Metastatic Melanoma News

Metastatic Melanoma: The Immunotherapy Approach - OncLive



OncLive
 
Metastatic Melanoma: The Immunotherapy Approach 
OncLive
Panelists: Jeffrey S. Weber, MD, PhD, NYU Langone Health; Reinhard G. Dummer, MD, University Hospital of Zurich; Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein; Michael A. Postow, MD, Memorial Sloan Kettering Cancer Center; ...

 


Neutrophil to Lymphocyte Ratio Predicts Survival in Metastatic Melanoma - OncLive



OncLive
 
Neutrophil to Lymphocyte Ratio Predicts Survival in Metastatic Melanoma 
OncLive
The neutrophil-to-lymphocyte ratio (NLR) is an independent factor for overall survival (OS) in patients with metastatic melanoma, whether they receive targeted therapy or immunotherapy. In a retrospective analysis performed in patients treated at a ...

 


Altering Tumor Microenvironment May Offer New Approach to Metastatic Melanoma Therapy - Genetic Engineering & Biotechnology News



Genetic Engineering & Biotechnology News
 
Altering Tumor Microenvironment May Offer New Approach to Metastatic Melanoma Therapy 
Genetic Engineering & Biotechnology News
Researchers at the Wistar Institute and the Medical University of Vienna say they have identified the role of tumor-infiltrating or tumor-associated B cells (TABs) in melanoma progression and resistance to targeted therapy. A molecular mechanism that ...

 


The Value of Ipi/Nivo in Treating Metastatic Melanoma - OncLive



OncLive
 
The Value of Ipi/Nivo in Treating Metastatic Melanoma 
OncLive
Panelists: Jeffrey S. Weber, MD, PhD, NYU Langone Health; Reinhard G. Dummer, MD, University Hospital of Zurich; Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein; Michael A. Postow, MD, Memorial Sloan Kettering Cancer Center; ...

and more » 


Metastatic Melanoma research start-up receives $2 million grant - The Daily Iowan



Metastatic Melanoma research start-up receives $2 million grant 
The Daily Iowan
The University of Iowa start-up company Viewpoint Molecular Targeting LLC received a $2 million grant from the National Cancer Institute in September for further pre-clinical research on a treatment for metastatic melanoma. This is not the first grant ...

 


Timing Targeted and Immunotherapies for Metastatic Melanoma - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Timing Targeted and Immunotherapies for Metastatic Melanoma 
Cancer Therapy Advisor
Up to 15% of patients diagnosed with melanoma will develop metastatic tumors, against which chemotherapy is ?largely ineffective,? with response rates as low as 5%.1,2 Approximately 45% of metastatic tumors harbor BRAFV600 mutations that can be ...
Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report. UroToday
Metastatic Melanoma Market ? Global Market Opportunity Assessment Study 2024. Find Market Research By Abhishek Budholiya (press release) (blog)

all 3 news articles » 


Data in Melanoma: Observing Trials and Unmet Needs - OncLive



OncLive
 
Data in Melanoma: Observing Trials and Unmet Needs 
OncLive
I need to say, they're 2 women in their early 50s who are both suffering from metastatic melanoma, stage 4. One of them had a very high tumor load and she was suffering, and we believed she was dying immediately. She was in such bad shape: ECOG 2 to 3, ...

and more » 


Melanoma cells rewire to resist drug treatment - Science Daily



Science Daily
 
Melanoma cells rewire to resist drug treatment 
Science Daily
In 2014, new combination therapies to treat patients with metastatic melanoma hit the market, helping extend the lives of those with this aggressive disease. Yet unfortunately, after several months of treatment, almost all patients on the regimen ...

and more » 


Prima BioMed (PBMD) Says IMP321 New Data Accepted for Presentation at SITC - StreetInsider.com



Prima BioMed (PBMD) Says IMP321 New Data Accepted for Presentation at SITC 
StreetInsider.com
Prima BioMed Ltd (NASDAQ: PBMD) announces that new data investigating the use of eftilagimod alpha (IMP321), the Company's lead product candidate, in combination with pembrolizumab in metastatic melanoma patients in Australia that have had either ...
Prima BioMed Ltd (PBMD) Broker Price Targets For The Coming Week Fiscal Standard

all 17 news articles » 


Expert Addresses Ongoing Challenges in Melanoma - OncLive



OncLive
 
Expert Addresses Ongoing Challenges in Melanoma 
OncLive
I was invited to [Post-Chicago Melanoma] to talk about a couple different topics?one of them has to do with how to treat liver metastases for melanoma. It is a very difficult problem for a variety of reasons, one being that it is possible that the ...